Targeting the crosstalk between metabolism and epigenetics to treat liver fibrosis

几乎所有与肝脏疾病相关的发病率和死亡率都是纤维化的结果，最终导致肝功能衰竭或肝癌。由于没有抗纤维化药物，因此需要新的药物开发方法。我们已经发现了这种药物开发的新策略，通过以高度靶向的方式修改特定基因（RARRES1）的表达，从而中断细胞驱动纤维化所需的能量产生。

Virtually all liver disease related morbidity and mortality is a consequence of fibrosis that culminates in liver failure or liver cancer. Since anti-fibrotic drugs are not available, new approaches to drug development are required. We have discovered a novel strategy for such drug development by modifying the expression of a specific gene (RARRES1) in a highly targeted manner and thereby interrupting the energy production that is needed by cells to drive fibrosis.